Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

OptiNose, Inc. (OPTN)

1.88   0 (0%) 11-28 09:40
Open: 1.79 Pre. Close: 1.88
High: 1.88 Low: 1.82
Volume: 9,405 Market Cap: 157(M)

Technical analysis

as of: 2022-11-28 9:20:48 AM
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 3.36     One year: 4.23
Support: Support1: 1.66    Support2: 1.38
Resistance: Resistance1: 2.88    Resistance2: 3.63
Pivot: 2.35
Moving Average: MA(5): 1.83     MA(20): 2.62
MA(100): 3.4     MA(250): 2.77
MACD: MACD(12,26): -0.5     Signal(9): -0.4
Stochastic oscillator: %K(14,3): 8.3     %D(3): 7
RSI: RSI(14): 28.9
52-week: High: 4.3  Low: 1.48
Average Vol(K): 3-Month: 154 (K)  10-Days: 402 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ OPTN ] has closed above bottom band by 33.0%. Bollinger Bands are 310.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 9 days. This is a sign that the current trend might continue.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.91 - 1.93 1.93 - 1.94
Low: 1.74 - 1.75 1.75 - 1.76
Close: 1.86 - 1.88 1.88 - 1.9

Company Description

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It is also developing OPN-019 that combines liquid EDS device with an antiseptic. The company has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail; and Inexia Limited to develop, manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. OptiNose, Inc. was founded in 2000 and is headquartered in Yardley, Pennsylvania.

Headline News

Mon, 28 Nov 2022
National organ transplant overseer takes hard stance against Penn State Health - Indiana Gazette

Tue, 22 Nov 2022
7 years of HOPE - UNOS

Mon, 21 Nov 2022
Optinose Shares Slide Premarket After Public Offering Plans >OPTN - MarketWatch

Sun, 13 Nov 2022
OptiNose, Inc. (OPTN) Q3 2022 Earnings Call Transcript - Seeking Alpha

Fri, 11 Nov 2022
Healthcare Stocks on the Move Friday: SGHT, TNYA, MGTA, BWV, AIRS, MYO, TOI, OPTN - InvestorsObserver

Thu, 10 Nov 2022
UNOS seeks new CEO to be voice for diverse needs of organ donation and transplant community - UNOS

Financial Analysis

Price to Book Value: Underperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Drug Manufacturers—Specialty & Generic
Shares Out. 84 (M)
Shares Float 51 (M)
% Held by Insiders 6.3 (%)
% Held by Institutions 74.7 (%)
Shares Short 2,650 (K)
Shares Short P.Month 2,550 (K)

Stock Financials

EPS -1.28
EPS Est Next Qtl 0
EPS Est This Year 0.64
EPS Est Next Year 0
Book Value (p.s.) -0.88
Profit Margin (%) -96.7
Operating Margin (%) -76
Return on Assets (ttm) -31.3
Return on Equity (ttm) 0
Qtrly Rev. Growth -8
Gross Profit (p.s.) 0.78
Sales Per Share 0.93
EBITDA (p.s.) -0.71
Qtrly Earnings Growth 0
Operating Cash Flow -67 (M)
Levered Free Cash Flow -38 (M)

Stock Valuations

PE Ratio -1.48
PEG Ratio -0.1
Price to Book value -2.14
Price to Sales 2.01
Price to Cash Flow -2.36

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.